On the evening of July 1, Huaxi Biotech (688363) issued a performance forecast. It is expected to achieve operating income of 1.847 billion yuan to 1.942 billion yuan in the first half of 2021, an increase of 95% to 105% year-on-year; net profit is 347 million yuan to 374 million yuan , An increase of 30% to 40% year-on-year. Regrettably, the pre-increasing performance did not bring about stock price growth. On July 2, Huaxi Biotechnology closed at 279.31 yuan per share, down 6.59% that day, and had a total market value of 134.1 billion yuan.
The company stated that with the gradual improvement of the impact of the epidemic, the company’s revenue from all business segments has achieved certain growth. Among them, the company’s raw material business and medical device business have grown steadily, and the functional skin care product business segment has continued to grow at a high rate in the first half of 2021. Achieve substantial growth.
It is reported that Huaxi Biotech has a full hyaluronic acid industry chain platform integrating R&D, production and sales, and has a solid market position in the market for hyaluronic acid raw materials. In early 2021, the Health Commission approved the expansion of the use of sodium hyaluronate to beverages, candy and other fields. The industry is generally optimistic and believes that sodium hyaluronate has great potential market space in functional foods. In the first half of the year, new functional food products using sodium hyaluronate as the raw material flocked to the market. Huaxi Biotechnology launched its own brand of sodium hyaluronate “Black Zero” with the advantage of raw materials. (Source: Shuzheng Kangxu)